No Data
Indaptus Therapeutics Provides 2025 Outlook, Launching Decoy20 Combination Cohort With BeiGene's Tislelizumab, Expanding Clinical Sites Beyond 8, Updating Higher Dose Cohort, First Patient Dosed In Combination, Focus On Cancer Challenges
Express News | FTSE China A50 Index Futures Surge Over 1%; Pinduoduo Nearly 5% Premarket
Xiaomi Expands EV Charging Options, Partners With NIO, XPeng, and Li Auto for Greater Network Access
BeiGene Gains FDA Nod for TEVIMBRA, Marking Key Progress in Oncology Treatments
BeiGene to Rebrand as BeOne Medicines With Oncology-Focused New Nasdaq Ticker "ONC"
Reported Earlier, BeiGene Secures Global Licensing Agreement For Novel MAT2A Inhibitor SYH2039 To Target MTAP-Deleted Solid Tumors